Complexity of Plasmodium falciparum infections and antimalarial drug efficacy at 7 sites in Uganda

Journal of Infectious Diseases

Volumn 193, Issue 8, 2006, Pages 1160-1163

  Lee, Sulggi A ^a   Yeka, Adoke ^c   Nsobya, Samuel L ^d   Dokomajilar, Christian ^b   Rosenthal, Philip J ^b   Talisuna, Ambrose ^c   Dorsey, Grant ^b,e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MINISTRY OF HEALTH   (Uganda)

^d MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTESUNATE; CHLOROQUINE; FANSIDAR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG EFFICACY; ENDEMIC DISEASE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; TREATMENT FAILURE; UGANDA;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HUMANS; INFANT; MALARIA, FALCIPARUM; MIDDLE AGED; ODDS RATIO; PLASMODIUM FALCIPARUM; TREATMENT OUTCOME; UGANDA;

EID: 33645759449     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/501473     Document Type: Article

References (11)

1. Wernsdorfer WH. Epidemiology of drug resistance in malaria. Acta Tropica 1994; 56:143-56.
2. Bendixen M, Masangeni HA, Pedersen BV, Shayo D, Bodker R. Diversity of Plasmodium falciparum populations and complexity of infections in relation to transmission intensity and host age: a study from the Usambara Mountains, Tanzania. Trans R Soc Trop Med Hyg 2001; 95:143-8.
3. Bakyaita N, Dorsey G, Yeka A, et al. Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda. Am J Trop Med Hyg 2005; 72:573-80.
4. Yeka A, Banek K, Bakyaita N, et al. Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med 2005; 2:e190.
5. World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria, 2003. Available at: http://ww.emro.who.int/rbm/publications/protocolwho.pdf. Accessed 15 November 2005.
6. Cattamanchi A, Kyahayinze D, Hubbard A, Rusenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg 2003; 68:133-9.
7. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002; 2:209-18.
8. Dorsey G, Gasasira AF, Machekano R, Kamya MR, Staedke SG, Hubbard A. The impact of age, temperature, and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda. Am J Trop Med Hyg 2004; 71:531-6.
9. Deck HP, Felger I, Huber W, et al. Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase 111 trial of the malaria vaccine SPf66. J Infect Dis 1997; 175:921-6.
10. Haywood M, Conway DJ, Weiss H, et al. Reduction in the mean number of Plasmodium falciparum genotypes in Gambian children immunized with the malaria vaccine SPf66. Trans R Soc Trop Med Hyg 1999; 93(Suppl 1):65-8.
11. Alloueche A, Milligan P, Conway DJ, et al. Protective efficacy of the RTS,S/AS02 Plasmodium falciparum malaria vaccine is not strain specific. Am J Trop Med Hyg 2003; 68:97-101.